An Acute Presentation of Marchiafava-Bignami Disease

Madison T Gray¹, G Bryan Young², Adrian Budhram^{1

3}, Robert R Hammond^{1

3}

Affiliations

¹ Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
² Grey Bruce Health Services, Owen Sound, Ontario, Canada.
³ Department of Clinical Neurosciences, Western University, London, Ontario, Canada.

Madison T Gray et al. Ann Neurol. 2023 Oct.

. 2023 Oct;94(4):806-808.

doi: 10.1002/ana.26757. Epub 2023 Aug 14.

Madison T Gray¹, G Bryan Young², Adrian Budhram^{1

3}, Robert R Hammond^{1

3}

¹ Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
² Grey Bruce Health Services, Owen Sound, Ontario, Canada.
³ Department of Clinical Neurosciences, Western University, London, Ontario, Canada.

No abstract available

References

1. Heinrich A, Runge U, Khaw AV. Clinicoradiologic subtypes of Marchiafava-Bignami disease. J Neurol 2004;251:1050-1059.
1. Fernandes LMP, Bezerra FR, Monteiro MC, et al. Thiamine deficiency, oxidative metabolic pathways and ethanol-induced neurotoxicity: how poor nutrition contributes to the alcoholic syndrome, as Marchiafava-Bignami disease. Eur J Clin Nutr 2017;71:580-586.
1. Tung C-S, Wu S-L, Tsou J-C, et al. Marchiafava-Bignami disease with widespread lesions and complete recovery. AJNR Am J Neuroradiol 2010;31:1506-1507.
1. Lim KY, Kim S-I, Kim H, et al. Toxic leukoencephalopathy with axonal spheroids caused by chemotherapeutic drugs other than methotrexate. BMC Neurol 2022;22:288.